In the large TAILORx trial, researchers followed 9,719 women with ER-positive, HER2-negative breast cancer to see whether a gene test could steer chemotherapy decisions. For women over 50 with mid-range Oncotype DX scores, they found no significant difference in overall survival between those who had chemotherapy added and those who did not. Women under 50 with a medium score showed some benefit from the extra treatment.
That result is a large part of why the test has the standing it does. Oncotype DX is made by Genomic Health, now part of Exact Sciences. The Breast Recurrence Score version looks at the activity of 21 genes in a sample of tumor tissue taken during a biopsy or surgery and returns a score from 0 to 100. It is meant for people with early stage, estrogen receptor-positive, HER2-negative disease, and it estimates both the risk of distant recurrence and the likely payoff from chemotherapy.
How the evidence is graded
The National Comprehensive Cancer Network (NCCN) lists the Breast Recurrence Score as its preferred gene expression test for predicting chemotherapy benefit. The strength of the evidence depends on menopausal status. For postmenopausal women the NCCN rates it level 1, the highest grade, which means the opinion rests on reviews of randomized controlled trials. For premenopausal women the rating is 2A, based on reviews of cohort studies that follow groups of participants over time.
Studies have reported that testing changed the chemotherapy decision for as many as 30 percent of doctors treating ER-positive, HER2-negative patients. The test tends to be most useful when the cancer is medium risk and it is unclear whether chemotherapy would improve survival.
Gaps in the data
The record is thinner outside breast cancer. Oncotype DX also exists for prostate and colon cancer, each analyzing 12 genes, but fewer studies back those versions. A 2021 study by the American Society of Clinical Oncology found the prostate test may help predict 20-year prostate cancer-specific mortality and the chance of distant spread. For stage 2 and 3 colon cancer, the first validation came from the SUNRISE study.
There is also a accuracy problem the National Cancer Institute has flagged. Oncotype DX breast testing may be less accurate for Black women than for non-Hispanic white women. A 2021 study of Black women in the United States found lower predictive accuracy, and its authors suggested the test may need recalibrating for some racial groups.
The test costs about $4,000. The Genomic Access Program helps patients work through insurance coverage and payment, and offers financial assistance to people without insurance.
Consult your doctor for medical advice.





